Medullary Thyroid Carcinoma: a 30-year Experience at One Institution in Korea

Overview

Journal Ann Surg Treat Res

Specialty General Surgery

Date 2016 Dec 2

PMID 27904849

Citations 12

Authors

Cho Rok Lee

Sohee Lee

Haiyoung Son

Eunjeong Ban

Sang-Wook Kang

Jandee Lee

Jong Ju Jeong

Kee-Hyun Nam

Woong Youn Chung

Cheong Soo Park

Affiliations

Soon will be listed here.

Abstract

Purpose: The objective of this study was to review the clinical outcome and prognosis of patients with sporadic and hereditary medullary thyroid cancer (MTC) who were treated at a single tertiary hospital in Korea.

Methods: We retrospectively reviewed the case files of 85 patients treated from August 1982 to February 2012.

Results: In all, 65 patients (76.5%) had sporadic MTC and 20 patients (23.5%) had hereditary MTC. Patients in the sporadic group were older than in the hereditary group (P < 0.001). However, the hereditary group had more tumor multiplicity (P < 0.001) and bilaterality (P < 0.001). Neither survival rate was significantly different between the sporadic and hereditary groups (P = 0.775 and P = 0.866). By multivariate analysis, distant metastasis was a significant prognostic factor for overall and progression-free survival.

Conclusion: In general, patients with MTC have favorable outcomes. Distant metastasis appears to be the strongest predictor of overall and progression-free survival.

Citing Articles

Distinct Impacts of Clinicopathological and Mutational Profiles on Long-Term Survival and Recurrence in Medullary Thyroid Carcinoma.

Oh M, Jung K, Choi H, Chai Y, Cho S, Kim S Endocrinol Metab (Seoul). 2024; 39(6):877-890.

PMID: 39497455 PMC: 11695486. DOI: 10.3803/EnM.2024.2027.

Establishment and validation of a nomogram model for predicting distant metastasis in medullary thyroid carcinoma: An analysis of the SEER database based on the AJCC 8th TNM staging system.

Chen Z, Mao Y, You T, Chen G Front Endocrinol (Lausanne). 2023; 14:1119656.

PMID: 36875492 PMC: 9975719. DOI: 10.3389/fendo.2023.1119656.

Prognostic value of LODDS in medullary thyroid carcinoma based on competing risk model and propensity score matching analysis.

Cao Z, Weng X, Huang J, Long X Updates Surg. 2022; 74(5):1551-1562.

PMID: 35821560 DOI: 10.1007/s13304-022-01320-7.

Long-Term Outcomes and Causes of Death among Medullary Thyroid Carcinoma Patients with Distant Metastases.

Park H, Yang H, Heo J, Kim T, Kim S, Chung J Cancers (Basel). 2021; 13(18).

PMID: 34572897 PMC: 8469864. DOI: 10.3390/cancers13184670.

Hereditary medullary thyroid carcinoma syndromes: experience from western India.

Diwaker C, Sarathi V, Jaiswal S, Shah R, Deshmukh A, Thomas A Fam Cancer. 2021; 20(3):241-251.

PMID: 33392850 DOI: 10.1007/s10689-020-00219-9.

References

Wells Jr S, Asa S, Dralle H, Elisei R, Evans D, Gagel R . Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015; 25(6):567-610. PMC: 4490627. DOI: 10.1089/thy.2014.0335. View

Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F . Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996; 81(4):1619-22. DOI: 10.1210/jcem.81.4.8636377. View

Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E . RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007; 92(12):4725-9. DOI: 10.1210/jc.2007-1005. View

Marsh D, Theodosopoulos G, Martin-Schulte K, Richardson A, Philips J, Roher H . Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2003; 88(4):1866-72. DOI: 10.1210/jc.2002-021155. View

Dottorini M, Assi A, Sironi M, Sangalli G, SPREAFICO G, Colombo L . Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 1996; 77(8):1556-65. DOI: 10.1002/(SICI)1097-0142(19960415)77:8<1556::AID-CNCR20>3.0.CO;2-Y. View

Raue F, Kotzerke J, REINWEIN D, Schroder S, Roher H, DECKART H . Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig. 1993; 71(1):7-12. DOI: 10.1007/BF00210956. View

Saad M, Ordonez N, Rashid R, Guido J, HILL Jr C, HICKEY R . Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 1984; 63(6):319-42. View

Pacini F, Castagna M, Cipri C, Schlumberger M . Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010; 22(6):475-85. DOI: 10.1016/j.clon.2010.05.002. View

Bugalho M, Domingues R, Santos J, Catarino A, Sobrinho L . Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery. 2006; 141(1):90-5. DOI: 10.1016/j.surg.2006.03.025. View

10.

Fromigue J, de Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M . Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006; 91(7):2496-9. DOI: 10.1210/jc.2005-2401. View

11.

Grozinsky-Glasberg S, Benbassat C, Tsvetov G, Feinmesser R, Peretz H, Shimon I . Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid. 2007; 17(6):549-56. DOI: 10.1089/thy.2006.0229. View

12.

Clark J, Fridman T, Odell M, Brierley J, Walfish P, Freeman J . Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope. 2005; 115(8):1445-50. DOI: 10.1097/01.mlg.0000168114.90852.a6. View

13.

Farndon J, Leight G, Dilley W, Baylin S, Smallridge R, Harrison T . Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg. 1986; 73(4):278-81. PMC: 11431776. DOI: 10.1002/bjs.1800730411. View

14.

Gharib H, McConahey W, Tiegs R, Bergstralh E, Goellner J, Grant C . Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc. 1992; 67(10):934-40. DOI: 10.1016/s0025-6196(12)60923-9. View

15.

Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R . The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996; 276(19):1575-9. View

16.

Kebebew E, Ituarte P, Siperstein A, Duh Q, Clark O . Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000; 88(5):1139-48. DOI: 10.1002/(sici)1097-0142(20000301)88:5<1139::aid-cncr26>3.0.co;2-z. View

17.

Figlioli G, Landi S, Romei C, Elisei R, Gemignani F . Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res. 2012; 752(1):36-44. DOI: 10.1016/j.mrrev.2012.09.002. View

18.

Bergholm U, Bergstrom R, Ekbom A . Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer. 1997; 79(1):132-8. DOI: 10.1002/(sici)1097-0142(19970101)79:1<132::aid-cncr19>3.0.co;2-5. View

19.

Modigliani E, Cohen R, Campos J, Conte-Devolx B, Maes B, Boneu A . Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998; 48(3):265-73. DOI: 10.1046/j.1365-2265.1998.00392.x. View

20.

Gulben K, Berberoglu U, Boyabatli M . Prognostic factors for sporadic medullary thyroid carcinoma. World J Surg. 2005; 30(1):84-90. DOI: 10.1007/s00268-005-7949-z. View